grant
Elucidating and overcoming T cell dysfunction in pancreatic cancer
Organization UNIVERSITY OF MINNESOTALocation MINNEAPOLIS, UNITED STATESPosted 7 Aug 2025Deadline 31 Jul 2030
NIHUS FederalResearch GrantFY2025AffinityAgonistAnimal ModelAnimal Models and Related StudiesAntitumor ResponseBp50CD40CD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCDW40CancersCell Communication and SignalingCell SignalingCell TherapyCellular biologyCharacteristicsChronicClinicalCombination immunotherapyCombined Modality TherapyDataDesmoplasticDesmoplastic ReactionDevelopmentDiagnosisDiseaseDisorderDysfunctionEngineeringFunctional disorderFundingImmuneImmune SurveillanceImmune mediated therapyImmunesImmunityImmunologic SurveillanceImmunologically Directed TherapyImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunosurveillanceImmunotherapyImplantInflammatoryIntracellular Communication and SignalingMGC9013MHC ReceptorMajor Histocompatibility Complex ReceptorMalignant NeoplasmsMalignant Pancreatic NeoplasmMalignant TumorMalignant neoplasm of pancreasMediatingMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorModelingModificationMultimodal TherapyMultimodal TreatmentMyeloid CellsNeoplasm MetastasisOutcomePD 1PD-1PD-L1 antibodyPD-L1 pathwayPD1PDL1 pathwayPancreas CancerPancreas Ductal AdenocarcinomaPancreatic CancerPancreatic Ductal AdenocarcinomaPathogenesisPhysiopathologyResistanceSecondary NeoplasmSecondary TumorSignal PathwaySignal TransductionSignal Transduction SystemsSignalingSurvival RateT cell receptor based immunotherapyT cell receptor cellular immunotherapyT cell receptor engineered therapyT cell receptor immunotherapyT cell responseT-Cell Antigen ReceptorsT-Cell ReceptorT-Cell Receptor TherapyT-Cell Receptor TreatmentT-Cell Receptor based TherapyT-Cell Receptor based TreatmentT-CellsT-LymphocyteT8 CellsT8 LymphocytesTCR T cell immunotherapyTCR T cell therapyTCR TherapyTCR based T cell immunotherapyTCR based TherapyTCR based immune therapyTCR based immunotherapyTCR based treatmentTCR immunotherapyTNFRSF5TNFRSF5 geneTestingTimeTumor Necrosis Factor Receptor Superfamily Member 5 GeneWorkaPD-L1aPD-L1 antibodiesanti programmed cell death ligand 1anti programmed cell death protein ligand 1anti-PD-(L)1anti-PD-L1anti-PD-L1 antibodiesanti-PD-L1 monoclonal antibodiesanti-PDL-1anti-PDL1anti-PDL1 antibodiesanti-tumor responseantiPD-L1biological signal transductioncancer metastasiscancer microenvironmentcell based interventioncell biologycell mediated interventioncell mediated therapiescell-based therapeuticcell-based therapycellular therapeuticcellular therapycheck point blockadecheckpoint blockadecombination therapycombinatorialcombinatorial immunotherapycombined modality treatmentcombined treatmentdesigndesigningdevelopmentaldual immunotherapyengineered T cellsgenetically engineered T-cellsimmune check point blockadeimmune checkpoint blockadeimmune resistanceimmune suppressionimmune suppressive activityimmune suppressive functionimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmune-resistantimmuno therapyimmunoresistanceimmunosuppressive activityimmunosuppressive functionimmunosuppressive responsemalignancymodel of animalmulti-modal therapymulti-modal treatmentneoplasm/cancernovelp50pancreatic malignancypathophysiologyprogrammed cell death 1programmed cell death ligand 1 pathwayprogrammed cell death protein 1programmed cell death protein ligand 1 pathwayprogrammed death 1resistance to therapyresistantresistant to therapysle2systemic lupus erythematosus susceptibility 2therapeutic resistancetherapy resistantthymus derived lymphocytetransgenic T- cellstreatment resistancetumortumor cell metastasistumor microenvironmentαPD-L1αPD-L1 antibodiesαPDL1
Description preview
PROJECT SUMMARY
Pancreatic ductal adenocarcinoma (PDA) is a lethal disease notoriously resistant to therapy including immune
checkpoint blockade. Meanwhile, immunotherapy targeting the PD-1:PD-L1 pathway is inducing stunning clinical
outcomes in other advanced malignancies. However, the underlying mechanisms governing immune
surveillance and…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click